Denintuzumab mafodotin

Drug Profile

Denintuzumab mafodotin

Alternative Names: Anti-CD19-mafodotin; Anti-CD19-mcMMAF; SGN-19A; SGN-CD19A

Latest Information Update: 31 Jan 2017

Price : $50

At a glance

  • Originator Seattle Genetics
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Immunomodulators; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diffuse large B cell lymphoma; Follicular lymphoma
  • Phase I Acute lymphoblastic leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 03 Nov 2016 Preclinical data from in non-Hodgkin lymphoma released by Seattle Genetics
  • 03 Nov 2016 Denintuzumab is still in phase I trials for Non-Hodgkin's-lymphoma and Acute-lymphoblastic-leukaemia in USA
  • 03 Nov 2016 Pharmacodynamics data from a preclinical trial in Non-Hodgkin's-lymphoma released by Seattle Genetics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top